Abstract: Acoustic wave device includes: a piezoelectric substrate; a first IDT located on the piezoelectric substrate; and a second IDT located on the piezoelectric substrate and connected in series to the first IDT, wherein the first IDT and the second IDT share a single common bus bar as a first bus bar of two bus bars of the first IDT and a first bus bar of two bus bars of the second IDT, and the common bus bar has a width not more than two times a wavelength of an acoustic wave propagating through the first and second IDTs, the common bus bar connects to no dummy electrode finger facing a tip of an electrode finger connected to a second bus bar of the two bus bars of the first IDT and the second IDT across a gap.

Abstract: The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.

Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.

Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.

Abstract: A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.

Abstract: The present invention aims to provide a mesenchymal stem cell attractant capable of attracting a mesenchymal stem cell; and others. The present invention provides a mesenchymal stem cell attractant containing at least one selected from the group consisting of an extract of a Bodhi tree, an extract of the root bark of Paeonia suffruticosa Andrews, an extract of Mallotus philippinensis, an extract of Uncaria gambir, an extract of Pashanbheda, and an extract of a plant belonging to the genus Prunus.

Abstract: Provided are an attractant for bone marrow stem cells containing at least one of cinnamtannin B1 and pentagalloylglucose, and a method for attracting bone marrow stem cells in which bone marrow stem cells are attracted by the attractant.

Abstract: The present invention aims to provide a mesenchymal stem cell attractant capable of attracting a mesenchymal stem cell; and others. The present invention provides a mesenchymal stem cell attractant containing at least one selected from the group consisting of an extract of a Bodhi tree, an extract of the root bark of Paeonia suffruticosa Andrews, an extract of Mallotus philippinensis, an extract of Uncaria gambir an extract of Pashanbheda, and an extract of a plant belonging to the genus Prunus.

Abstract: Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above, the present invention also provides methods for promoting lymphangiogenesis which comprise the step of locally administering HGFs or proteins functionally equivalent thereto to affected areas in patients with lymphedema.

Abstract: An acoustic wave device includes: a substrate; an acoustic wave resonator that is formed on the substrate; a first wiring line that is formed on the substrate and is electrically coupled to the acoustic wave resonator; and a second wiring line that is electrically coupled to the first wiring line, at least a part of the second wiring line being formed immediately above the acoustic wave resonator across an air gap.

Abstract: Acoustic wave device includes: a piezoelectric substrate; a first IDT located on the piezoelectric substrate; and a second IDT located on the piezoelectric substrate and connected in series to the first IDT, wherein the first IDT and the second IDT share a single common bus bar as a first bus bar of two bus bars of the first IDT and a first bus bar of two bus bars of the second IDT, and the common bus bar has a width not more than two times a wavelength of an acoustic wave propagating through the first and second IDTs, the common bus bar connects to no dummy electrode finger facing a tip of an electrode finger connected to a second bus bar of the two bus bars of the first IDT and the second IDT across a gap.

Abstract: A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.

Abstract: Provided are an attractant for bone marrow stem cells containing at least one of cinnamtannin B1 and pentagalloylglucose, and a method for attracting bone marrow stem cells in which bone marrow stem cells are attracted by the attractant.

Abstract: A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-?B decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-?B decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.

Abstract: Provided are a novel therapeutic agent and therapeutic method for prostatic cancers. More specifically, a prostatic cancer therapeutic/prophylactic agent having a viral envelope vector, particularly a Sendai viral envelope vector, as an active ingredient, the therapeutic/prophylactic agent which is an apoptosis induction promoter, the therapeutic/prophylactic agent used for prostatic cancers whose androgen susceptibility has been partially or completely reduced, and a melanoma therapeutic/prophylactic agent containing a Sendai viral envelope vector as the only active ingredient, and the like are provided.

Abstract: The present invention for the first time demonstrated that: (1) bone marrow-derived pluripotent tissue stem cells can be induced in peripheral blood by intravenously administering tissue extract prepared from isolated skin pieces; (2) the substance in the isolated skin pieces, which is responsible for mobilizing bone marrow-derived pluripotent tissue stem cells to peripheral blood, is HMGB1; and (3) HMGB1 with the activity of mobilizing bone marrow-derived pluripotent stem cells to peripheral blood can be easily purified from cultured cells.

Abstract: The present invention aims to provide a mesenchymal stem cell attractant capable of attracting a mesenchymal stem cell; and others. The present invention provides a mesenchymal stem cell attractant containing at least one selected from the group consisting of an extract of a Bodhi tree, an extract of the root bark of Paeonia suffruticosa Andrews, an extract of Mallotus philippinensis, an extract of Uncaria gambir an extract of Pashanbheda, and an extract of a plant belonging to the genus Prunus.

Abstract: It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.

Abstract: An electronic component includes a substrate, a functional element formed on the substrate, a plurality of terminals including a first terminal electrode connected to the functional element and a second terminal electrode layered on the first terminal electrode, and a feed line, one end of which is electrically connected to the first terminal electrode and the other end of which reaches an edge of the substrate, wherein the feed line includes a first portion directly reaching the edge, and a second portion branching from the first portion and then reaching the edge.

Abstract: There is provided a method of fabricating an electronic device including flip-chip mounting a device chip on a substrate, and supplying solder between adjacent device chips by supplying the solder on the device chips and applying heat and pressure on the solder, and a contact angle of the device chip and the solder is greater than 90° with the solder melted.